A national survey of over six million US cancer survivors found that roughly 1 in 12 reported using cannabis in 2021, with nearly half citing medical reasons. Use was more common among younger, male, and Black survivors and in states with legalized cannabis, but the cross-sectional design cannot determine whether cannabis is helping or harming this population.

There are approximately 18 million cancer survivors living in the United States, and cannabis legalization is expanding rapidly across state lines. Yet until now, population-level data on how many cancer survivors actually use cannabis, and why, have been remarkably scarce. Without reliable prevalence estimates, oncology providers lack the baseline information they need to ask the right questions, tailor counseling, or anticipate drug interactions. This study fills a critical descriptive gap at a moment when both patient interest and legal access are accelerating faster than the evidence base can keep up.

Cannabis use among cancer survivors has been an area of growing clinical interest but limited epidemiologic characterization. While small clinical studies and patient surveys have documented that cancer patients frequently use cannabis for symptom management, including pain, nausea, and anxiety, nationally representative prevalence data have been largely absent. The Behavioral Risk Factor Surveillance System (BRFSS) is the largest ongoing US health survey, conducted by telephone, and in 2021 an optional cannabis module was administered in 23 states. This study leveraged that module to estimate the weighted prevalence of past-30-day cannabis use among cancer survivors (excluding non-melanoma skin cancer) and to identify clinicodemographic predictors using multivariable logistic regression and a secondary difference-in-difference analysis examining the effect of state-level legalization over time.

Among approximately 6.2 million weighted cancer survivors, 8.8% (roughly 542,868) reported cannabis use. Nearly half (47.3%) cited medical reasons, compared with only 24.2% in the general population. Use frequency was split almost evenly between low frequency (fewer than 20 days per month) and high frequency (20 or more days per month). In adjusted models, younger age (OR 4.0 for under 65 versus 65 and older), male sex (OR 1.54), Black race (OR 1.35), lower income, current smoking, and heavy alcohol use were each independently associated with higher odds of cannabis use. The difference-in-difference analysis found that state-level recreational legalization was associated with a 4.5% absolute increase in cannabis use among cancer survivors, a smaller increase than the 5.2% observed in the general population. Key limitations include the cross-sectional design, self-report bias, exclusion of skin cancer, restriction to 23 self-selected states, and the absence of clinical data on cancer type, treatment stage, or symptom burden. The authors emphasize that prospective studies are needed to clarify whether cannabis use in this population reflects unmet symptom management needs or other behavioral patterns.

This study does something genuinely valuable: it gives us a number. Roughly 1 in 12 cancer survivors is using cannabis, and nearly half say they are using it for medical purposes. That proportion is substantial and, frankly, probably an undercount given the stigma around self-reporting. What the study cannot tell us, and what I find myself most wanting to know, is what symptoms are driving that use, what products and dosing patterns these patients are choosing, and whether any of it is being discussed with their oncologists. The gap between “patients are using cannabis” and “patients are getting good guidance about cannabis” remains enormous.

In my own practice, I find that cancer survivors are among the most deliberate cannabis users I see. They tend to have specific, identifiable goals: managing chronic pain, improving sleep after treatment, or addressing persistent nausea. I use data like this to normalize the conversation, not to prescribe a particular regimen, but to make clear that a significant minority of survivors are already using cannabis and that talking about it openly leads to safer, more effective choices. The demographic patterns here, particularly higher use among younger and lower-income survivors, also signal that equitable access to informed guidance needs much more attention.

This study sits squarely in the descriptive epidemiology phase of research, which is exactly where the field needs to be for this population. Before we can design effective interventional trials of cannabis for cancer-related symptoms, we need to understand who is already using it, how often, and in what legal context. The finding that cancer survivors are meaningfully more likely than the general population to cite medical reasons for use (47.3% versus 24.2%) lends credibility to the hypothesis that unmet symptom burden is a primary driver, though the study lacks the clinical detail to confirm it. The difference-in-difference finding, showing a smaller legalization-associated increase among cancer survivors than the general population, is intriguing and may suggest that medical motivation partially decouples survivor use from recreational policy shifts.

From a pharmacological standpoint, the high concurrent rates of tobacco (21.5%) and heavy alcohol use (19.1%) among cannabis-using cancer survivors raise real safety concerns, including additive hepatot

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care